CONCLUSIONS: Our data suggest that CAF ERa could be applied as a prognostic marker to predict the recurrence-free survival, and targeting CCL5 and IL6 may be applied as an alternative therapeutic approach to reduce M2 type macrophages and PCa invasion in PCa patients with low or little ERa expression in CAF cells.
INTRODUCTION AND OBJECTIVES: While new prostate cancer (CaP) treatments (Abiraterone and Enzalutamide) have improved survival in castration resistant prostate cancer (CRPC), their benefits are short-lived and drug resistance develops likely due to numerous adaptive mutations. Accumulating evidence has established the androgen regulated TMPRSS2-ERG fusion as a common oncogenic driver that contributes to the early development and progression of over half of CaP. Therefore, ERG oncoprotein and ERG dependent pathways are promising targets for CaP therapy in early stages when cancer is most responsive to treatment. We previously identified a small molecule inhibitor, ERGi-USU, which selectively inhibits ERG protein and cell growth in ERG positive tumor cell lines and mouse xenograft models. In an effort to further develop ERGi-USU with enhanced efficacy we performed detailed structure-activity relationship (SAR) evaluation of ERGi-USU core structure and developed new derivatives.
METHODS: Based on SAR of the core structure of ERGi-USU, 48 new derivatives were designed and synthesized by substitutions with alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl or hydroxyl groups. The new ERGi-USU derivatives were evaluated for inhibition of cell growth and ERG protein levels in the TMPRSS2-ERG fusion harboring CaP cell line, VCaP. Four of these compounds have been selected for evaluation of ERG selectivity by defining IC50 in ERG positive malignant cells (VCaP, KG1, MOLT-4 and COLO320), ERG negative CaP cell line (LNCaP) or ERG positive normal primary endothelium-derived cells (HUVEC).
RESULTS: Like parental compound, four new ERGi-USU derivatives exhibited inhibition of cell growth and ERG protein levels in ERG positive VCaP, KG1, MOLT-4 and COLO320 cell lines, with no or minimal effects on LNCaP and HUVEC cells. One of the new derivatives (ERGi-USU#6) showed increased efficacy for cell growth inhibition (IC50¼0.074mM) compared to the parental ERGi-USU (IC50¼0.200mM). Other three new compounds showed similar IC50 as the ERGi-USU.
CONCLUSIONS: Comprehensive evaluation of ERGi-USU derivatives along with parental compound has continued to underscore selective inhibition of ERG positive tumor cells by these small molecules.
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INTRODUCTION AND OBJECTIVES: Radiation therapy (RT)
is a standard treatment for prostate cancer (PCA). Although dose escalation increases local control, further escalation hampers toxicity. Further improvement will be possible by addition of adjuvant therapies, which can synergize with radiation and thus improve efficacy.
METHODS: Human prostate cancer cell lines were used to test the combination of radiation and (Nexrutine, Nx). Global transcriptome profiling was used to delineate the mechanism. Transgenic adenocarcinomas of mouse prostate (TRAMP) mice were treated with Nx or radiation alone, or combination of Nx plus radiation to assess Nx as a radiation adjuvant. Histopathology and immunohistochemistry of survival targets were used as primary and secondary outcomes respectively. Contingency table analysis with c2 tests were used to characterize the differences in categorical factors between experimental groups. Means were compared and tested with independent t-test across experimental groups for continuous outcomes and repeated-measures. General linear modeling was used to examine treatment differences over time.
RESULTS: We have identified ribosomal protein S6K (RPS6KB1) that is upregulated in prostate tumors and its expression is correlated with pathological stage. Knockdown of RPS6KB1 not only decreased colony forming ability of aggressive prostate cancer cells but also increased their sensitivity toward radiation-induced survival inhibition. Furthermore, we have identified a natural compound (Nexrutine, Nx) but not its biologically active components to inhibit the growth of prostate cancer cells in combination with radiation. Importantly, combination studies demonstrated strong synergistic interaction between Nx and radiation both in vitro in multiple prostate cancer cell lines and in vivo using TRAMP model. Mechanistic investigations including transcriptome analysis showed that RPS6KB1 as an important player in radio-resistance as well as in Nx-mediated radio-sensitization. Furthermore, Nx pretreatment prolongs G2/M checkpoint block following radiation by sustained activation of Wee1 kinase and phosphorylation of cdc2. Importantly cells pretreated with Nx showed increased staining for g-H2AX relative to radiation alone suggesting that increased DNA damage. Remarkably all of these events lead to induction of apoptosis.
CONCLUSIONS: Taken together, this report provides scientific evidence in support of the use of Nx as an adjuvant in prostate cancer patients receiving radiotherapy and further emphasizes RPS6KB1 as a novel target for prostate cancer treatment.
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